Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre ‐specified subgroup with heart failure

ConclusionsConsistent with the overall AMBER trial results, this pre ‐specified subgroup analysis in patients with HF, resistant hypertension and advanced chronic kidney disease demonstrated that patiromer enabled more persistent use of spironolactone by reducing the risk of hyperkalaemia.

Source: European Journal of Heart Failure - May 24, 2020 Category: Cardiology Authors: Patrick Rossignol, Bryan Williams, Martha R. Mayo, Suzette Warren, Susan Arthur, Gail Ackourey, William B. White, Rajiv Agarwal Tags: Research Article Source Type: research